AdAlta (1AD) 2023年年度报告「ASX」.pdf

1、ANNUALREPORTADALTA LTDABN 92 120 332 925FOR THE YEAR ENDED30 JUNE 20232AdAlta Limited Annual Report 2023 ABN 92 120 332 925CONTENTSCORPORATE DIRECTORY 3CHAIRS LETTER 5CEO AND MANAGING DIRECTORS LETTER 6DIRECTORS REPORT 7AUDITORS INDEPENDENCE DECLARATION 28STATEMENT OF PROFIT OR LOSS AND OTHERCOMPREH

2、ENSIVE INCOME 29STATEMENT OF FINANCIAL POSITION 30STATEMENT OF CHANGES IN EQUITY 31STATEMENT OF CASH FLOWS 32NOTES TO THE FINANCIAL STATEMENTS 33DIRECTORS DECLARATION 52INDEPENDENT AUDITORS REPORT TO THE MEMBERS OF ADALTA LIMITED 53SHAREHOLDER INFORMATION 573AdAlta Limited Annual Report 2023 ABN 92

3、120 332 925CORPORATE DIRECTORYDIRECTORSDr Paul MacLemanDr Timothy OldhamDr Robert PeachDr David Fuller Ms Elizabeth McCall(Resigned on 24 March 2023)Dr James Williams(Alternate to Elizabeth McCall)(Resigned on 24 March 2023)COMPANY SECRETARY Mr Cameron Jones REGISTERED OFFICEUnit 15/2 Park DriveBund

4、oora Vic 3083 AUDITORDry Kirkness(Audit)Pty Ltd Ground Floor,50 Colin Street West Perth,Western Australia 6005SHARE REGISTRYAutomic Registry Services Level 5 126 Phillip Street Sydney,NSW 2000 Tel:1300 288 664 STOCK EXCHANGE LISTINGAdAlta Limited shares are listed on the Australian Securities Exchan

5、ge.ASX CODE1AD WEBSITE.au4AdAlta Limited Annual Report 2023 ABN 92 120 332 9255AdAlta Limited Annual Report 2023 ABN 92 120 332 925CHAIRS LETTERDear fellow shareholder,During FY23,we were pleased to maintain momentum,while further extending both the value and scope of AdAltas portfolio of i-body ena

6、bled assets.Our lead product,AD-214,is a first in class,next generation antibody therapeutic for the treatment of fibrotic diseases including lung fibrosis(specifically Idiopathic Pulmonary Fibrosis(IPF)and Interstitial Lung Disease(ILD),kidney fibrosis,eye fibrosis and some cancers.Our priority for